{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:29:05Z","timestamp":1778894945790,"version":"3.51.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Primary cardiac paragangliomas are rare tumors. Metastatic disease is even rarer. Surgical management is technically challenging, and sometimes even impossible. Available therapeutic modalities for metastatic disease include external beam radiation therapy as well as systemic treatments, namely <jats:sup>131<\/jats:sup>I-MIBG and more recently, peptide receptor radionuclide therapy (PRRT) with <jats:sup>177<\/jats:sup>Lu-DOTATATE. To our knowledge, this is the first case of progressive unresectable cardiac paraganglioma with intracardiac extension treated with dosimetry based personalized PRRT to be reported. This case is of particular interest since it documents for the first time the efficacy, and especially the safety of the <jats:sup>177<\/jats:sup>Lu-DOTATATE PRRT in this precarious context for which therapeutic options are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>A 47-year-old man with no medical history consulted for rapidly decreasing exercise tolerance. The investigation demonstrated an unresectable progressing metastatic cardiac paraganglioma with intracardiac extension. The patient was treated with personalized <jats:sup>177<\/jats:sup>Lu-DOTATATE PRRT and showed complete symptomatic and partial anatomical responses, with a progression-free survival of 13\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PRRT with <jats:sup>177<\/jats:sup>Lu-DOTATATE should be considered for inoperable cardiac paraganglioma. No major hemodynamic complications were experienced. Therapy resulted in safety and substantially improved quality of life.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.705271","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T17:52:47Z","timestamp":1626976367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Alexis","family":"Huot Daneault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Desaulniers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Mathieu","family":"Beauregard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Arsenault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"April","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9ric","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Alexandre","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2015.08.006","article-title":"Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, and Treatment","volume":"25","author":"Kiernan","year":"2016","journal-title":"Surg Oncol Clin N Am"},{"key":"B2","volume-title":"Pathology and Genetics of Tumours of Endocrine Organs","author":"DeLellis RA","year":"2004"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-15-3-356","article-title":"Evolving Concepts in the Pathophysiology, Diagnosis, and Treatment of Pheochromocytoma","volume":"15","author":"Bravo","year":"1994","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E996","DOI":"10.1503\/cmaj.170067","article-title":"Cardiac Paraganglioma","volume":"189","author":"Tam","year":"2017","journal-title":"CMAJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.ajem.2015.07.025","article-title":"A Peculiar Etiology of Acute Heart Failure: Adrenergic Myocarditis","volume":"33","author":"Polito","year":"2015","journal-title":"Am J Emergency Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.04.158","article-title":"Cardiac Paraganglioma: Clinical Presentation, Diagnostic Approach and Factors Affecting Short and Long-Term Outcomes","volume":"166","author":"Khan","year":"2013","journal-title":"Int J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199906000-00001","article-title":"Clinical Experience Over 48 Years With Pheochromocytoma","volume":"229","author":"Richard","year":"1999","journal-title":"Ann Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000499497","article-title":"Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma","volume":"109","author":"Mak","year":"2019","journal-title":"Neuroendocrinology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/endoabs.60.P21","article-title":"Utility of PRRT Therapy in Invasive Intra-Cardiac Paraganglioma","volume":"60","author":"Ultan Healy","year":"2018","journal-title":"Endocrine Abstracts"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3688-2","article-title":"Personalized (177)Lu-Octreotate Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumours: A Simulation Study","volume":"44","author":"Del Prete","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40658-018-0224-9","article-title":"Accuracy and Reproducibility of Simplified QSPECT Dosimetry for Personalized (177)Lu-Octreotate PRRT","volume":"5","author":"Del Prete","year":"2018","journal-title":"EJNMMI Phys"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2012.02.040","article-title":"Contemporary Surgical Management of Cardiac Paragangliomas","volume":"93","author":"Ramlawi","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2006.02.061","article-title":"Successful Perioperative Management of a Middle Mediastinal Paraganglioma","volume":"132","author":"Jun Matsumoto","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy With Cyclophosphamide, Vincristine and Dacarbazine for Malignant Paraganglioma and Pheochromocytoma: Systematic Review and Meta-Analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients With Advanced Pheochromocytoma or Paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG Therapy for Malignant Paraganglioma and Phaeochromocytoma: Systematic Review and Meta-Analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14106","article-title":"Anil Bhansali Peptide Receptor Radionuclide Therapy in the Management of Advanced Pheochromocytoma and Paraganglioma: A Systematic Review and Meta-Analysis","volume":"91","author":"Swayamjeet Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/cancers11070909","article-title":"Favorable Outcome in Patients With Pheochromocytoma and Paraganglioma Treated With (177)Lu-DOTATATE","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-Specific-Activity-(131)I-MIBG Versus (177)Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma","volume":"27","author":"Jha","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12149-020-01541-z","article-title":"TSBS. 131i-MIBG Negative Progressive Symptomatic Metastatic Paraganglioma: Response and Outcome Witj 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy","volume":"35","author":"Parghane","year":"2021","journal-title":"Ann Nucl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0778","article-title":"Pheochromocytoma Crisis Induced by Glucocorticoids: A Report of Four Cases and Review of the Literature","volume":"158","author":"Rosas","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/jcm9072203","article-title":"Prevention and Management of Hormonal Crisis During Theragnosis With LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal","volume":"9","author":"Del Olmo-Garcia","year":"2020","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28010015","article-title":"Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study","volume":"28","author":"Sistani","year":"2020","journal-title":"Curr Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.705271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T17:52:49Z","timestamp":1626976369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.705271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":24,"alternative-id":["10.3389\/fendo.2021.705271"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.705271","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"article-number":"705271"}}